Citations

Mayo Clinic

Showing 10 of 108572 citations.

Incorporating Functional Annotations for Fine-Mapping Causal Variants in a Bayesian Framework Using Summary Statistics
Chen, Wenan , McDonnell, Shannon K. , Thibodeau, Stephen N. , Tillmans, Lori S. , Schaid, Daniel J. , McDonnell, Shannon K

Genetics | September 21, 2016 | Volume: 204 | Issue: 3 | Pages: 933-958

10.1534/genetics.116.188953 | PMID 27655946 Get It

Abstract Functional annotations have been shown to improve both the discovery power and fine-mapping accuracy in genome-wide association studies. However, the optimal strategy to incorporate the large number of existing annotations is still not clear. In this study, we propose a Bayesian framework to incorporate functional annotations in a systematic manner. We compute the maximum a posteriori solution and use cross validation to find the optimal penalty parameters. By extending our previous fine-mapping method CAVIARBF into this framework, we require only summary statistics as input. We also derived an exact calculation of Bayes factors using summary statistics for quantitative traits, which is necessary when a large proportion of trait variance is explained by the variants of interest, such as in fine mapping expression quantitative trait loci (eQTL). We compared the proposed method with PAINTOR using different strategies to combine annotations. Simulation results show that the proposed method achieves the best accuracy in identifying causal variants among the different strategies and methods compared. We also find that for annotations with moderate effects from a large annotation pool, screening annotations individually and then combining the top annotations can produce overly optimistic results. We applied these methods on two real data sets: a meta-analysis result of lipid traits and a cis-eQTL study of normal prostate tissues. For the eQTL data, incorporating annotations significantly increased the number of potential causal variants with high probabilities.
The Influence of Processing and Storage Conditions on Renal Protein Biomarkers
Giesen, Callen D., Lieske, John C.

Clinical Journal of the American Society of Nephrology | September 21, 2016 | Volume: 11 | Issue: 10 | Pages: 1726-1728

10.2215/cjn.08800816 | PMID 27654929 Get It

Pregnancy-Related Changes of Amino Acid and Acylcarnitine Concentrations: The Impact of Obesity
Donovan, Brittney M., Fleener, Diedre, Bedell, Bruce, Borowski, Kristi, Borowski, Kristi S, Ryckman, Kelli K.

American Journal of Perinatology Reports | September 21, 2016 | Volume: 06 | Issue: 03 | Pages: e329-e336

10.1055/s-0036-1592414 | PMID 27672481 Get It

Chronic Subthreshold Cortical Stimulation to Treat Focal Epilepsy
Nickels, Katherine , Wetjen, Nicholas M. , Stead, Matt, Lundstrom, Brian Nils, Van Gompel, Jamie, Britton, Jeffrey, Wetjen, Nicholas, Lundstrom, Brian N. , Gompel, Jamie J. Van , Britton, Jeffrey W. , Worrell, Gregory A. , Nickels, Katherine C

JAMA Neurology | September 21, 2016 | Volume: 73 | Issue: 11 | Pages: 1370

10.1001/jamaneurol.2016.2857 | PMID 27654625 Get It

A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer
Vijai, Joseph , Topka, Sabine , Villano, Danylo , Ravichandran, Vignesh , Maria, Ann, Gaddam, Pragna, Lincoln, Anne , Kazzaz, Sarah A. , Wenz, Brandon M., Carmi, Shai , Schrader, Kasmintan A. , Hart, Steven N. , Lipkin, Steve M., Walsh, Michael F. , Zhang, Liying , Lejbkowicz, Flavio, Rennert, Hedy S., Weitzel, Jeffrey N. , Daly, Mark J., Nathanson, Katherine L. , Rennert, Gad , Offit, Kenneth , Maxwell, Kara N. , Thomas, Tinu , Neuhausen, Susan L. , Stadler, Zsofia , Robson, Mark E. , Domchek, Susan M. , Couch, Fergus J. , Norton, Larry , Schrader, Intan , Rennert, Gad , Weitzel, Jeffrey N , Joseph, Vijai , Hart, Steven N , Nathanson, Katherine L , Ravichandran, Vignesh , Topka, Sabine

Cancer Discovery | September 21, 2016 | Volume: 6 | Issue: 11 | Pages: 1267-1275

10.1158/2159-8290.cd-16-0487 | PMID 27655433 Get It

Abstract Known gene mutations account for approximately 50% of the hereditary risk for breast cancer. Moderate and low penetrance variants, discovered by genomic approaches, account for an as-yet-unknown proportion of the remaining heritability. A truncating mutation c.325C>T:p.Arg109* (R109X) in the ATP-dependent helicase ERCC3 was observed recurrently among exomes sequenced in BRCA wild-type, breast cancer–affected individuals of Ashkenazi Jewish ancestry. Modeling of the mutation in ERCC3-deficient or CRISPR/Cas9-edited cell lines showed a consistent pattern of reduced expression of the protein and concomitant hypomorphic functionality when challenged with UVC exposure or treatment with the DNA alkylating agent IlludinS. Overexpressing the mutant protein in ERCC3-deficient cells only partially rescued their DNA repair–deficient phenotype. Comparison of frequency of this recurrent mutation in over 6,500 chromosomes of breast cancer cases and 6,800 Ashkenazi controls showed significant association with breast cancer risk (ORBC = 1.53, ORER+ = 1.73), particularly for the estrogen receptor–positive subset (P < 0.007). Significance: A functionally significant recurrent ERCC3 mutation increased the risk for breast cancer in a genetic isolate. Mutated cell lines showed lower survival after in vitro exposure to DNA-damaging agents. Thus, similar to tumors arising in the background of homologous repair defects, mutations in nucleotide excision repair genes such as ERCC3 could constitute potential therapeutic targets in a subset of hereditary breast cancers. Cancer Discov; 6(11); 1267–75. ©2016 AACR. This article is highlighted in the In This Issue feature, p. 1197
Therapeutic drug monitoring of mexiletine at a large academic medical center
Nei, Scott D. , Danelich, Ilya , Lose, Jennifer M., Leung, Lydia Yuk Ting, Asirvatham, Samuel J. , Danelich, Ilya M, McLeod, Christopher J. , Asirvatham, Samuel J

SAGE Open Medicine | September 21, 2016 | Volume: 4 | Issue: No issue available | Pages: No page available

10.1177/2050312116670659 | PMID 27708780 Get It

Introduction: The therapeutic trough range for mexiletine (0.8–2 mcg/mL) was largely established in the setting of arrhythmia prophylaxis following myocardial infarction. Objective: Describe the usage patterns of serum mexiletine concentrations and the impact of these concentrations on mexiletine dosing in modern practice for ventricular arrhythmia treatment. Methods: A single-center, retrospective analysis was conducted using the electronic medical record to identify serum mexiletine concentrations drawn between December 2004 and December 2014. The primary endpoint was the incidence of mexiletine concentrations drawn as troughs. Secondary outcomes included the incidence of mexiletine concentrations that prompted a dose change, association between adverse events and elevated concentrations, and association between baseline characteristics and mexiletine concentrations. Results: A total of 237 individual concentrations were included for analysis with 109 (46.0%) drawn appropriately as trough concentrations. Only 31 (13.1%) of the 237 concentrations drawn prompted a dose change. Mexiletine was primarily used for the treatment of ventricular arrhythmias (96.2%), and 108 (45.6%) concentrations were drawn in an effort to assess efficacy. The median concentration was statistically different between patients with and without an adverse event (0.8 vs 0.7 mcg/mL, respectively; p = 0.017), but may not represent a clinical significance. Patients with hepatic dysfunction had higher median concentrations compared to those without hepatic dysfunction (1.30 vs 1.07 mcg/mL; p = 0.01). Conclusion: Mexiletine concentrations are often drawn at inappropriate times and seldom influence a dose change. This study suggests that routine monitoring of mexiletine concentrations may not be necessary; however, therapeutic drug monitoring may be considered in patients with hepatic dysfunction or to confirm mexiletine absorption in patients where this represents a concern.
NeuroDebian Virtual Machine Deployment Facilitates Trainee-Driven Bedside Neuroimaging Research
Cohen, Alexander L. , Kenney‐Jung, Daniel , Botha, Hugo , Tillema, Jan‐Mendelt , Botha, Hugo , Cohen, Alexander

Journal of Child Neurology | September 21, 2016 | Volume: 32 | Issue: 1 | Pages: 29-34

10.1177/0883073816668113 | PMID 27655470 Get It

Freely available software, derived from the past 2 decades of neuroimaging research, is significantly more flexible for research purposes than presently available clinical tools. Here, we describe and demonstrate the utility of rapidly deployable analysis software to facilitate trainee-driven translational neuroimaging research. A recipe and video tutorial were created to guide the creation of a NeuroDebian-based virtual computer that conforms to current neuroimaging research standards and can exist within a HIPAA-compliant system. This allows for retrieval of clinical imaging data, conversion to standard file formats, and rapid visualization and quantification of individual patients’ cortical and subcortical anatomy. As an example, we apply this pipeline to a pediatric patient’s data to illustrate the advantages of research-derived neuroimaging tools in asking quantitative questions “at the bedside.” Our goal is to provide a path of entry for trainees to become familiar with common neuroimaging tools and foster an increased interest in translational research.
Inclusion of Hypoglycemia in Clinical Practice Guidelines and Performance Measures in the Care of Patients With Diabetes
Rodríguez‐Gutiérrez, René , Ospina, Naykky Singh , Shah, Nilay D. , Montori, Víctor M. , Group, for the Hypoglycemia as a Quality Measure in Diabetes Study, McCoy, Rozalina G. , Lipska, Kasia J. , Group, for the Hypoglycemia as a Quality Measure in Diabetes Study, Montori, Victor M , Singh Ospina, Naykky

JAMA Internal Medicine | September 21, 2016 | Volume: 176 | Issue: 11 | Pages: 1714

10.1001/jamainternmed.2016.5046 | PMID 27653613 Get It

Computer decision support for acute kidney injury: current and future
Kashani, Kianoush

Current Opinion in Critical Care | September 21, 2016 | Volume: 22 | Issue: 6 | Pages: 520-526

10.1097/mcc.0000000000000353 | PMID 27652908 Get It

Purpose of review Growing awareness regarding the impact of acute kidney injury (AKI) as a grave consequence of critical illnesses resulted in the expansion of the need for early detection and appropriate management strategies. Clinical decision support systems (CDSS) can generate information to improve the care of AKI patients by providing point-of-care accurate patient-specific information and recommendations. Our objective is to describe the characteristics of CDSS and review the current knowledge regarding the impact of CDSS on patients in the acute care settings, and specifically for AKI. Recent findings Several recent systematic analyses showed the positive impact of CDSS on critically ill patients care processes. These studies also highlighted the scarcity of data regarding the effect of CDSS on the patient outcomes. In the field of AKI, there have been several reports to describe development and validation of homegrown CDSS and electronic alert systems. A large number of investigations showed the implementation of CDSS could improve the quality of AKI care; although, only in a very small subgroup of these studies patient outcomes improved. Summary The heterogeneity of these studies in their size, design, and conduct has produced controversial findings; hence, this has left the field completely open for further investigations.
Faculty Opinions recommendation of Microglia contact induces synapse formation in developing somatosensory cortex.
Wu, Long‐Jun , Eyo, Ukpong B

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 21, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726673180.793523231 Get It